Boehringer Ingelheim v. Laurus Labs: Consent Judgment After 1,653 Days
Boehringer Ingelheim brought a Hatch-Waxman infringement action against Laurus Labs and Laurus Generics in Delaware over patents covering empagliflozin tablets marketed as Jardiance. The parties reached a negotiated resolution entered as a consent judgment, ending consolidated proceedings spanning more than four and a half years.
Empagliflozin Generic Entry Dispute Ends in Consent Judgment
Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. filed this Hatch-Waxman patent infringement action on 7 November 2018 in the District of Delaware, asserting US9949998B2 and US7579449B2 against Laurus Labs Limited and Laurus Generics Inc. The case concerned Laurus's Abbreviated New Drug Application No. 212421 seeking FDA approval to market 10 mg and 25 mg empagliflozin tablets as generic versions of Jardiance. The action was consolidated with related Delaware proceedings Civil Action Nos. 18-1689-CFC and 19-1596-CFC.
The recorded basis of termination is Consent Judgment. The docket order states that Boehringer and Laurus agreed to terms and conditions representing a negotiated resolution of the consolidated civil actions, with the court entering a consent judgment incorporating defined terms for the asserted patents and the Laurus ANDA product. The specific terms of the negotiated resolution are not disclosed in the available public record.
The case ran for 1,653 days from filing to closure on 18 May 2023 — a timeline consistent with complex multi-patent Hatch-Waxman litigation involving consolidated actions. What drove the parties toward a negotiated resolution rather than a merits adjudication is not apparent from the public record, and no licensing terms, market-entry dates, or royalty arrangements are disclosed in the available docket materials.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 1653 days
Days from filing to consent judgment — a multi-year Hatch-Waxman timeline
US9949998B2 — Glucopyranosyl-substituted phenyl derivatives (empagliflozin)
Any pharmaceutical company developing SGLT-2 inhibitor compounds, formulating empagliflozin generics, or filing ANDAs referencing Jardiance should treat these patents as active enforcement risks. The consent judgment in this case resolved Boehringer's claims against Laurus without any invalidity ruling — meaning both patents' claims remain fully enforceable. R&D teams working on glucopyranosyl-substituted phenyl derivatives or related metabolic disease compounds should conduct a targeted FTO before advancing to clinical or regulatory stages.
Official order — verbatim text
The consent judgment order defines the '998 Patent (US9949998B2), the '637 Patent (US10258637), and the Laurus ANDA Product (ANDA No. 212421 for 10 mg and 25 mg empagliflozin tablets) as the operative subject matter of the agreed resolution. The judgment is framed as a negotiated resolution of all consolidated Delaware proceedings. No merits findings on infringement or validity are recorded; the specific obligations imposed on either party are not disclosed in the available public record.
Consent judgment: what the agreed resolution means for both parties
What a consent judgment means in Hatch-Waxman litigation
A consent judgment is a binding, court-entered judgment on terms agreed by the parties, ending the litigation with the same legal force as a litigated verdict. In a Hatch-Waxman context, it resolves the infringement dispute and can define conditions for ANDA approval and commercial activity. The court retains jurisdiction to enforce the judgment. The specific terms agreed between Boehringer and Laurus are not disclosed in the available public record.
Binding court-entered resolutionBoehringer secures a court-entered judgment protecting Jardiance patents
As the patent holder, Boehringer Ingelheim obtains a consent judgment that is enforceable against Laurus Labs and Laurus Generics with respect to the asserted patents and the defined ANDA product. The judgment provides a court-sanctioned resolution without requiring a full merits trial. Whether it includes any admission of infringement or validity concession by Laurus is not stated in the available record.
Enforceable judgment for plaintiffLaurus Labs bound by agreed terms on its empagliflozin ANDA
Laurus Labs Limited and Laurus Generics Inc. are subject to a binding consent judgment governing their ANDA No. 212421 for 10 mg and 25 mg empagliflozin tablets. The judgment defines obligations with respect to the Laurus ANDA product as it exists on the effective date and as amended in the ordinary course of business. The specific commercial or regulatory consequences for Laurus are not disclosed in the available public record.
ANDA product terms agreedConsent judgment signals continued Jardiance patent enforcement posture
The resolution of this consolidated multi-year action by consent judgment — rather than a merits ruling — leaves the validity and enforceability of the asserted empagliflozin patents undisturbed by judicial determination. Other generic manufacturers monitoring this docket should note that Boehringer has demonstrated willingness to litigate to a court-entered judgment. The undisclosed terms mean market-entry timing for Laurus's generic cannot be inferred from this record.
Patent enforceability preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | /Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Laurus Labs Limited | Individual | /Search in Eureka ↗ |
| Co-Defendant | Laurus Generics Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Defendant counsel | Daniel J. Ritterbeck | Attorney | Counsel for Laurus Labs LimitedSearch in Eureka ↗ |
| Defendant counsel | Dennies Varughese, Pharm.D | Attorney | Counsel for Laurus Labs LimitedSearch in Eureka ↗ |
| Defendant counsel | Jeremy S. Cole | Attorney | Counsel for Laurus Labs LimitedSearch in Eureka ↗ |
| Defendant counsel | Joseph H. Kim | Attorney | Counsel for Laurus Labs LimitedSearch in Eureka ↗ |
| Defendant counsel | Nirav N. Desai | Attorney | Counsel for Laurus Labs LimitedSearch in Eureka ↗ |
| Defendant law firm | Flaster Greenburg PC | Law Firm | Representing Laurus Labs LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the SGLT-2 inhibitor patent space
Forward-looking patent and R&D intelligence derived from Boehringer Ingelheim's empagliflozin portfolio and the broader SGLT-2 inhibitor innovation landscape.
Boehringer's empagliflozin patent family: depth and continuation activity
Boehringer Ingelheim's empagliflozin IP estate extends well beyond the two asserted patents. Monitoring continuation filings, method-of-treatment claims, and formulation patents in this family can reveal where Boehringer is shoring up protection — and where claim gaps may exist for design-around strategies or generic entry planning.
Boehringer SGLT-2 portfolioSGLT-2 inhibitor filing trends: next-generation compound and combination patents
The SGLT-2 inhibitor class continues to generate significant filing activity in combination therapies, cardiovascular indications, and renal protection. Tracking new glucopyranosyl-substituted phenyl derivative patents and SGLT-2/DPP-4 combination claims can help R&D teams identify crowded spaces and emerging white space before committing to development programmes.
SGLT-2 filing trendsLaurus Labs' patent activity in diabetes and cardiovascular API space
Laurus Labs has been active in filing process and formulation patents around diabetes APIs including SGLT-2 inhibitors. Monitoring Laurus's own patent filings in this space provides intelligence on where they are building proprietary manufacturing or formulation positions that may differentiate their ANDA pipeline from commodity generic plays.
Laurus Labs IP activityAdjacent innovation: SGLT-2 delivery, dosage forms, and paediatric indications
The core empagliflozin compound space is densely patented, but adjacent opportunities exist in novel delivery systems, paediatric dosage formulations, fixed-dose combinations, and new metabolic indications not yet covered by Boehringer's enforced claims. Patent landscaping around these adjacencies may reveal lower-risk R&D entry points.
SGLT-2 white spaceSimilar Hatch-Waxman cases: SGLT-2 inhibitor patent actions in Delaware
Explore related Hatch-Waxman infringement actions asserting SGLT-2 inhibitor and empagliflozin patents before the Delaware District Court.
What this case signals for the SGLT-2 inhibitor patent landscape
A four-and-a-half-year consent judgment in a consolidated Jardiance ANDA action carries strategic weight for every generic filer in this class.
Boehringer's willingness to run multi-year ANDA litigation to judgment
The 1,653-day timeline and consolidation of three civil actions demonstrate that Boehringer is prepared to sustain extended Hatch-Waxman litigation across multiple defendants. Generic manufacturers seeking early entry against Jardiance patents should model litigation duration and cost accordingly.
Undisclosed terms create uncertainty for downstream generic market entrants
Because the consent judgment terms are not publicly disclosed, competitors cannot infer whether Laurus secured a specific launch date, royalty arrangement, or other commercial concession. This information asymmetry is a strategic disadvantage for subsequent ANDA filers assessing the landscape.
Boehringer-Ingelheim v Laurus — key questions answered
The case was resolved by consent judgment, entered on 18 May 2023 after 1,653 days of litigation. The parties — Boehringer Ingelheim and Laurus Labs Limited and Laurus Generics Inc. — agreed to a negotiated resolution of consolidated Delaware civil actions covering ANDA No. 212421 for generic empagliflozin tablets. The specific terms of the consent judgment are not disclosed in the available public record.
Boehringer Ingelheim asserted US9949998B2 (application US14/918727), covering glucopyranosyl-substituted phenyl derivatives including empagliflozin, and US7579449B2 (application US11/080150), covering pharmaceutical compositions and related methods. The consent judgment references these as the '998 Patent and the '637 Patent (US10258637 is also referenced in the verdict text). Neither patent received a merits validity or infringement ruling.
Laurus Labs filed ANDA No. 212421 seeking FDA approval to market 10 mg and 25 mg empagliflozin tablets as generic versions of Boehringer Ingelheim's Jardiance. This ANDA filing triggered Boehringer's 30-month stay litigation under the Hatch-Waxman Act. The consent judgment defines the Laurus ANDA Product as this ANDA as it exists on the effective date and as amended in the ordinary course of business.
Yes. The consent judgment covers consolidated proceedings including Civil Action Nos. 18-1758-CFC, 19-1596-CFC, and 18-1689-CFC, all in the District of Delaware. The verdict order states that the parties agreed to terms and conditions representing a negotiated resolution of these consolidated civil actions, ending all related proceedings in a single agreed judgment.
No. A consent judgment is a negotiated resolution entered by the court on agreed terms — it does not constitute a merits ruling on patent validity or infringement. The specific terms are not publicly disclosed, and no finding of invalidity, non-infringement, or infringement is recorded in the available docket. The asserted patents remain enforceable against third parties and are not impaired by this resolution.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.